The global CAUTI prevention urology products market size was estimated at USD 3.47 billion in 2025 and is predicted to increase from USD 3.73 billion in 2026 to approximately USD 7.08 billion by 2035, expanding at a CAGR of 7.39% from 2026 to 2035. The CAUTI prevention urology products market is growing, as these products improve evidence-based health care to lower the rate of CAUTI, it prevents of inappropriate short-term catheter used.

Market Overview

The CAUTI prevention urology products market is growing, as these products avoid unnecessary indwelling UC (IUC) insertion. Major catheter kits involve gloves to protect the hands, a sanitary pad to protect the catheter, and BZK/iodine wipes to eliminate insertion area bacteria.  A catheter-associated urinary tract infection (CAUTI) occurs when germs enter the urinary tract via a urinary catheter and cause infection.  Their applications prevent trauma to and frustration of the urethra. Catheter-related urinary tract infection (CAUTI) prevention urology products, like antimicrobial-coated catheters, closed drainage systems, and specialized supplement kits, are intended to significantly lower the challenges of infections, which are among the most common healthcare-related infections. Urinary tract infections are the most common type of infection that patients acquire in the hospital, and 75% of these are related to a urinary catheter. Challenges from CAUTIs cause patient discomfort, longer hospital stays, increased expenses, and mortality.

Key Indicators and Highlights

Regional Insights

How did North America dominate the Market in 2025?

In 2025, North America dominated the CAUTI prevention urology products market because this region has the largest medical care technology in the world, and the regulatory apparatus that oversees it is commensurately large and complex. Technology has transformed healthcare and led to faster, more precise diagnoses.  A fast-aging population needs more inpatient, outpatient, and specialized care, driving demand for facility capacity of CAUTI prevention urology products.

U.S. Market Trends

In the U.S., growing adoption of novel products, such as antimicrobial-coated urinary catheters, presents great strength in the prevention of urinary catheter-related challenges. In this region, UTIs increase with age, and a growing, older population in the U.S. means more people with weakened immune systems, diabetes, or incontinence challenges.

Asia Pacific: Increasing Aging Population

Asia Pacific is expected to see rapid growth in the CAUTI prevention urology products market, driven by rising rates of chronic disease in Asia Pacific, as well as lifestyle changes, increasing aging populations, and unhealthy consumption, which is increasing the demand for CAUTI prevention urology products. Asia-Pacific is the fastest ageing region globally and among the most vulnerable to climate change impacts. Massive spending in medical care infrastructure in China, India, and Southeast Asia is leading to growing hospital admissions and the volume of surgeries, thus increasing the applications of urinary catheters, which contribute to the growth of the market.

India Market Trends

India is significantly emerging as the world's capital of Diabetes, with a rising growth in complicated Urosepsis and UTI. Rising regulatory initiatives such as in 2025, Union Health Minister Shri J P Nadda Launched National Action Plan on Antimicrobial Resistance 2.0. Growing applications of silver alloy hydrogel-coated (SAH) catheter to prevent bacterial adhesion and colonization by producing a microcurrent, which drives the growth of the market.

• North America (Dominated): North America holds 45% of the market share, dominating due to high healthcare standards, large healthcare infrastructure, and greater awareness of infection prevention.
• Europe: Europe holds 25%, making it a significant player but not as dominant as North America due to varying healthcare policies and infrastructure across countries.
• Asia-Pacific (Fastest growing): At 20%, Asia-Pacific is growing rapidly, driven by healthcare modernization, increasing healthcare access, and rising awareness of CAUTI prevention.
• Latin America: Latin America holds 5% of the market share, with relatively lower penetration compared to other regions.
• Middle East & Africa: This region holds 5%, indicating minimal market share and slower growth due to less developed healthcare infrastructure and lower product demand.

Segmentation Analysis

By Product Insights

Which Product Segment Led the CAUTI Prevention Urology Products Market in 2025?

The preventive drainage devices segment held the dominant market in 2025, due to these products maintaining a closed, sterile drainage technology, which is significant for preventing the introduction of pathogens in the urinary tract.  These products are highly efficient in lowering the presence of asymptomatic bacteriuria, specifically in short-term catheterizations. Reducing the need for unnecessary catheter placement and lowering the duration of catheterization are the main strategies.

Sterile Circuit & Maintenance Systems

Whereas the sterile circuit & maintenance systems segment is the fastest-growing in the market, as sterile maintenance systems, involving the applications of pre-connected, sealed, and sterile catheters, have been shown to directly lower the incidence of CAUTI. It is important to follow aseptic handling practices and applications of sterile devices for insertion and placement of urinary catheters. Improved catheter maintenance practices and judicious catheter use significantly reduce CAUTI rates, thus enhancing patient outcomes and lowering healthcare-associated expenses.

CAUTI Prevention Urology Products Market Share, By Product, 2025 (%)

• Preventive Drainage Devices (Primary Prevention): Dominated: This segment holds the largest share at 40%, dominating due to its critical role in primary prevention and widespread adoption in healthcare facilities.
• External (Non-Invasive) Collection Systems: Does not dominate: With 25% of the market share, this segment does not dominate due to being more niche and less preferred in comparison to primary prevention methods.
• Sterile Circuit & Maintenance Systems (Mechanical Prevention): Fastest growing: Holding 20% of the market share, this segment is growing rapidly due to increasing emphasis on mechanical prevention techniques in urology.
• Procedural Support & "Insertion Bundles" (Aseptic Prevention): Does not dominate: This segment has 15% of the market share, representing a smaller focus area in the prevention spectrum and not yet dominating the market.

By Application Insights

Why did the Urinary Incontinence Management Products Segment Dominate the Market in 2025?

The urinary incontinence management products segment is dominant in the CAUTI prevention urology products market in 2025, as incontinence products play a significant role in enhancing the quality of life for patients affected by this illness. By providing improved comfort, increased independence, and affordable services, these products significantly advantage those who use them. Continence products supports to treat the symptoms of poor bladder and bowel control. They are used for a short time during treatment.

Benign Prostatic Hyperplasia (BPH) and Obstructive Urology

Whereas the benign prostatic hyperplasia (BPH) and obstructive urology segment, its recovery time is generally fast. It provides relief from symptoms, including urine control challenges. Relieving obstruction and protecting renal function are the significant therapeutic purposes of obstructive uropathy, which often includes surgical management, and the ureter catheter is a surgical instrument generally applied in surgery. They support preventing serious challenges, including recurrent urinary tract infections, kidney stones, and urosepsis.

CAUTI Prevention Urology Products Market Share, By Application, 2025 (%)

• Urinary Incontinence Management: Dominated: At 50%, this segment dominates due to the high prevalence of urinary incontinence and the essential need for prevention solutions in this area.
• Acute Surgical/Perioperative Care: Holding 25% of the market, this segment plays a significant role but is not as dominant compared to urinary incontinence management.
• Benign Prostatic Hyperplasia (BPH) and Obstructive Urology: Fastest growing: With 15% of the market, this segment is gaining momentum due to rising cases and greater awareness of BPH and obstructive urology.
• Neurogenic Bladder & Spinal Cord Injury (SCI): Does not dominate: At 10%, this segment has a smaller share, reflecting the relatively lower demand compared to other urology conditions.

By End Use Insights

Why did the Hospitals Segment Dominate the Market in 2025?

The hospitals segment is dominant in the CAUTI prevention urology products market in 2025, as these products support lowering CAUTI rates emphasizes the significance of continuous monitoring and reminders in healthcare practice to ensure patient safety. More focused on preserving bladder function, like urethral sphincter simulation, supports to enhance patient results by lowering discomfort and sustaining urinary function in long-term catheter users.

Home Care Setting

Whereas the home care setting segment is the fastest-growing in the market, as the home health care system allows eligible patients recovering from injuries, illness, or long-lasting conditions to remain where they feel most relaxed at home. Older adults recover rapidly, with fewer complications, at home than in a medical care setting. With consistent monitoring and education, home health care supports patients in managing health conditions and prevents avoidable emergency room visits.

CAUTI Prevention Urology Products Market Share, By End Use, 2025 (%)

• Hospitals (Dominated): Holding 55% of the market, hospitals dominate due to their large scale, critical need for CAUTI prevention products, and higher adoption rates of advanced urology solutions.
• Long Term Care Facilities: With 15% of the market share, this segment is smaller, as long-term care facilities have a more specific, niche demand for these products.
• Home Care Setting (Fastest growing): Holding 15%, this segment is gaining momentum due to the rise in home healthcare services and patient preference for non-hospital settings.
• Ambulatory Surgical Centers (ASCs): With 10% of the market, this segment has limited dominance, as ASCs typically have lower volumes of CAUTI prevention needs compared to hospitals.
• Others: This segment holds the smallest share, 5%, reflecting a minimal role in the overall market.